Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, Keytruda (Merck & Co.) plus Inlyta (Pfizer), Bavencio (Merck KGaA / Pfizer) plus Inlyta, are revolutionizing the treatment of advanced disease. Angiogenesis inhibitors such as Sutent (Pfizer), Votrient (Novartis), and Cabometyx (Exelixis / Ipsen) remain a key feature of first-line treatment. The entry and increased uptake of Cabometyx and Opdivo in this setting are beginning to shift Inlyta and Lenvima / Kisplyx (Eisai) plus Afinitor (Novartis) to later lines. Furthermore, following Sutent’s approval for high-risk early-stage (stage I-III) patients, multiple immune checkpoint inhibitors are anticipated to transition to the early-stage setting. The renal cell carcinoma therapy market remains highly competitive and dynamic, but the developer of an efficacious therapy can expect to reap high commercial rewards.

Questions Answered:

  • How are the early-stage and advanced or metastatic drug-treatable renal cell carcinoma populations defined, and how will drug-treatment rates evolve over the forecast period?
  • What is the current treatment landscape for renal cell carcinoma, and what are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
  • What is the outlook for key combination regimens in renal cell carcinoma? How will these combination regimens be differentiated, and which look the most promising?
  • Which emerging therapies do we forecast to enter the renal cell carcinoma market? What uptake and sales are these therapies anticipated to secure?

Contents Highlights

Geographies: United States, EU5, Japan

Primary Research: 19 country-specific interviews with thought-leading medical oncologists and urologists. Supported by survey data collected for this and other DRG research.

Epidemiology: Diagnosed and recurrent incidence of renal cell carcinoma by country, segmented by drug-treatable and -treated early-stage and locally advanced or metastatic disease and line of therapy.

Forecast: 10-year, annualized, drug-level sales and patient share of key renal cell carcinoma therapies through 2029, segmented by brands/generics and epidemiological subpopulations.

Emerging Therapies: Phase III/PR: 7 drugs; Phase II: 9 drugs; coverage of select preclinical and Phase I products.

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Renal Cell Carcinoma - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Priyanka Mehra, B.Tech; Mudasir Khan, M.P.H.; Sorcha Cassidy M.Res., Ph.D

Priyanka Mehra is a Business Insights Analyst in the oncology team at Decision Resources Group. She has 5+ years of work experience in pharmaceutical research and analytics, involving management and execution of various strategic analysis projects across multiple oncology indications, secondary and primary research and competitive intelligence. Previously, she worked as an Associate Consultant with Prescient Healthcare Group where she handled Biosimilars projects for global pharmaceutical clients and designed brand and commercial strategy solutions on a variety of therapy areas, including oncology, immunology and inflammatory diseases. Prior to Prescient, she worked as a Senior Analyst with Smart Analyst where she worked on indication prioritization and clinical landscapes for major oncology indications such as NHL, NSCLC and CRC. She has also worked as a Senior Analyst with BioXcel Corporation where she was involved with projects on clinical trials and pipeline analysis, performance benchmarking, scouting and product profiling.

Mudasir works as an associate epidemiologist within the epidemiology team at Decision Resources Group. He specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio.

Mudasir holds a masters in public health specializing in epidemiology from TISS, Mumbai.

Sorcha Cassidy M.Res., Ph.D., is an Associate Director in the Oncology team at Decision Resources Group.  Dr. Cassidy manages a team of analysts who conduct extensive primary and secondary market research on several Oncology indications across the major pharmaceutical markets. She also provides sales and client support across all oncology products. She has in-depth expertise in competitive intelligence, secondary and primary market research, and delivering strategic insights that address key client business questions. Dr. Cassidy holds an M.Res and Ph.D in Immunology from Imperial College London where she investigated the role of innate immune modulators (killer immunoglobulin-like receptors [KIR) on natural killer (NK) cells in various diseases and published several peer-reviewed papers. Prior to joining the company, Dr. Cassidy previously worked as a Market Research Manager in Janssen UK and has extensive experience working across multiple Oncology indications at GlobalData and FirstWord Pharma.

Related Reports

Renal Cell Carcinoma - Current Treatment - Detailed Expanded Analysis: Treatment Sequencing (US) 2020

This report is available to find out more click the link and fill out the form to get more details.

View Details

Renal Cell Carcinoma - Current Treatment - Detailed, Expanded Analysis (US)

The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the management of this disease. In a landscape previously dominated by mTOR and angi...

View Details

Renal Cell Carcinoma - Epidemiology - Mature Markets

DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across the major mature pharmace...

View Details